Skip to main content

Dasatinib Dose Optimization With Weekend Drug Holiday for Improved Tolerability in Chronic Myeloid Leukemia (DasaHIT): A German Chronic Myeloid Leukemia Alliance Randomized Trial

In brief

Weekend dasatinib achieved 78% molecular remission in first-line CML at 2 years

In a randomized trial, a 5-days-on, 2-days-off dasatinib schedule achieved major molecular remission in 78% of first-line patients at 24 months, close to 81% with daily dosing and meeting the trial's noninferiority criterion. Overall moderate-to-severe toxicity did not differ, though fluid around the lungs or heart was less frequent in a post hoc analysis; the approach was not shown to be noninferior in later-line patients.

Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology (Q1)
Published
13 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Paul La Rosée, Philipp Ernst, Christian Fabisch, Annamaria Brioli, Dominik Wolf, Lino L Teichmann, et al.
PMID
43024850
DOI
10.1200/JCO-26-00899

Why clinicians should know about it

  • Picked for Hematology (top studies of the week, 15 November 2026): Phase III CML dosing trial with molecular response and toxicity
  • Picked for Oncology and Radiation Oncology (top studies of the week, 15 November 2026): Phase III randomized trial of dasatinib dosing in CML

Abstract

PURPOSE: To compare standard-dose dasatinib 100 mg once daily with reduced-dose using a weekend drug holiday to improve tolerability for patients with chronic myeloid leukemia (CML). PATIENTS AND METHODS: Patients with chronic phase CML (CP-CML) were randomly assigned to either receive standard-of-care dasatinib 100 mg once daily or an intermittent dasatinib schedule (5 days on, 2 days [weekend] off) in a prospective multicenter phase III trial. Achievement of major molecular remission (MMR) at 24 months and a newly developed cumulative toxicity score were coprimary end points. RESULTS: Of 289 eligible patients, 147 were assigned to standard-of-care dasatinib and 142 to intermittent dosing. Eighty percent of patients received first-line treatment (n = 232). In the standard arm, 105 of 130 patients (81% [95% CI, 74% to 88%) achieved MMR at 24 months compared with 101 of 130 patients (78% [95% CI, 71% to 85%]) in the experimental arm resulting in noninferiority within the prespecified noninferiority margin of 15% (P = .009). Among second- or later-line patients, MMR at 24 months was 24% lower, failing noninferiority. Comparison of grade 2-4 toxicities revealed no significant difference between the treatment arms. However, a post hoc analysis of toxicities of special interest (pleural effusion/pericardial effusion) showed 21 of 130 patients (16%) in the standard arm versus 10 of 125 (8%) patients in the experimental arm (P = .0464). Consistently, health-related quality of life improved mainly in first-line patients, with more favorable outcomes in the experimental arm. CONCLUSION: Intermittent dasatinib dosing with weekend treatment holidays in patients with CP-CML is noninferior to continuous dosing with respect to MMR at 24 months, at least in the first-line setting. The incidence of pleural or pericardial effusion appears to be reduced compared with standard-of-care continuous dosing.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.